Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1200)	7/11/2005 12:13:19 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BIIB seems to have found support at the 33.85 level but it is still too early to tell wether it will try to close some of its Feb.28 downgap.<g> Volume is over 1.8M and the stock has a good amount of resistance from the 38.50 to the 40 level.<g> bigcharts.marketwatch.com BIIB sold to DNA its manufacturing facility at Oceanside,CA and it remains hopeful that Tysabri will return to the market later this summer if it gets an OK from the FDA after it reviews the results of an 8,000-patient safety evaluation. Beside its use for MS, Tysabri has also shown some positive results in Crohn's, but there is still concern on the reported cases of PML.<g> Besides the posibility of Tysabri come back, BIIB also has Rituxan which is effective in non-Hodgkins lymphoma and also may have some effect in patients with RA. Bernard